Drug Pricing: Page 2
-
CMS removes 7 drugs from list marked for price hike penalties
After revising its calculations, CMS removed Gilead’s cancer cell therapies Yescarta and Tecartus, as well as 5 other medicines, from the first set of drugs subject to rebates under a provision of the IRA.
By Christopher Newman • March 31, 2023 -
Ohio AG sues Cigna, Humana for alleged PBM price fixing
The state’s Attorney General David Yost called pharmacy benefit managers “modern gangsters,” claiming in a suit filed Monday they shared pricing information and drove up drug prices.
By Hailey Mensik • March 28, 2023 -
Explore the Trendline➔
RocheTrendlineBiosimilars
The arrival of lookalike competition to AbbVie’s Humira in the U.S. presents an opportunity, and a test, for the cost-saving potential of biosimilars.
By BioPharma Dive staff -
Moderna CEO defends price of COVID shot at Senate hearing
Stéphane Bancel said his company's planned quadrupling of the vaccine’s price covers the higher costs of commercial sales. Sen. Bernie Sanders called it part of industry’s “unprecedented level of corporate greed.”
By Christopher Newman • March 22, 2023 -
U.S. government again rejects call to seize Xtandi rights
The Biden administration plans to review federal “march-in” rights and consider whether price could be a reason to take control of patents for drugs developed with government funding.
By Jonathan Gardner • March 22, 2023 -
Sanofi joins other diabetes drugmakers in cutting insulin prices
The pharma is the last of the three major insulin suppliers to reduce U.S. list prices, responding to persistent criticism and policy changes that will affect Medicaid rebate payments.
By Christopher Newman • March 17, 2023 -
CMS lays out plans for negotiating drug prices
The guidance fills in details for one of the central pharmaceutical provisions of the Inflation Reduction Act, signaling how the agency will use its new authority.
By Christopher Newman • March 16, 2023 -
US names first drugs to face price hike penalty
Gilead’s cancer cell therapies Yescarta and Tecartus were among the slate of 27 drugs singled out by CMS for rebates under a provision of the IRA.
By Christopher Newman • March 15, 2023 -
Novo Nordisk follows Lilly in sharply cutting insulin prices
Responding to policy changes and pressure over high drug costs, the pharma is reducing the sticker price of four branded diabetes medicines by up to 75%.
By Delilah Alvarado • March 14, 2023 -
Biden takes fresh aim at drug prices with new budget plan
The proposal, viewed as a “non-starter” by one analyst, seeks to double the number of drugs Medicare can negotiate prices for and open up those talks more quickly.
By Christopher Newman • March 10, 2023 -
Biden’s plan to extend Medicare solvency targets prescription drugs
The proposal — part of a 2024 budget set to be released Thursday — would further reduce what Medicare pays for prescription drugs and raise taxes on Americans earning over $400,000.
By Rebecca Pifer • March 7, 2023 -
Sponsored by Phil
Harnessing data to improve patient access and optimize gross-to-net
Discover the data and metrics you should be tracking to evaluate patient access.
March 6, 2023 -
Lilly to lower insulin prices by 70%
The pharma company, along with its diabetes drug rivals Novo Nordisk and Sanofi, has long been under pressure over the high cost of insulin — scrutiny that has recently ramped up in the U.S.
By Jonathan Gardner • March 1, 2023 -
Sponsored by Phil
Harnessing data to improve patient access and optimize gross-to-net
Discover the data and metrics you should be tracking to evaluate patient access.
Feb. 27, 2023 -
Medicare maintains limits on Eisai’s new Alzheimer’s drug
Eisai and Biogen have data showing Leqembi slows cognitive decline, but CMS won’t budge until FDA converts its approval from accelerated to full.
By Jonathan Gardner • Feb. 23, 2023 -
Medicaid, with planned payment pilot, girds for influx of pricey gene therapies
The proposed model could help state Medicaid agencies explore different kinds of outcomes-based payment schemes, but may come too late to prepare for the first sickle cell gene therapy.
By Ned Pagliarulo • Feb. 21, 2023 -
Deep Dive // Patent thickets
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
Many top-selling products will lose patent protection by the end of the decade, putting pressure on companies to replace lost revenue with new medicines.
By Jonathan Gardner • Feb. 21, 2023 -
CMS plans trio of experiments aimed at lowering drug costs
The pilot programs could allow adjusted payments for drugs cleared under accelerated approval and help states manage the costs of gene therapies.
By Christopher Newman • Feb. 15, 2023 -
Medicare to collect drug price rebates starting in 2025
CMS laid out how it plans to implement a key provision of the Inflation Reduction Act, which requires drugmakers to pay rebates on price hikes within Medicare that are greater than inflation.
By Christopher Newman • Feb. 10, 2023 -
In address to Congress, Biden touts drug pricing law and pushes insulin cost caps
In his State of the Union speech, Biden threatened to veto any efforts to repeal the legislation and chastised drugmakers for the high cost of insulin.
By Kristin Jensen • Feb. 8, 2023 -
Patent thickets
Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug
The world’s best-selling drug will face pricing pressure as rivals try to steal share from AbbVie’s $20 billion-a-year flagship product in the U.S.
By Jonathan Gardner • Jan. 31, 2023 -
Moderna draws more lawmaker criticism for COVID vaccine pricing plan
Senators Warren and Welch urged the biotech to reconsider a planned price hike to between $110 and $130 a dose, and sought answers to a long list of questions.
By Kristin Jensen • Jan. 26, 2023 -
Pfizer expands not-for-profit pledge to include more medicines
The pharma is now committing to providing all of the roughly 500 products in its portfolio, including antibiotics and cancer drugs, to 45 lower-income countries.
By Kristin Jensen • Jan. 17, 2023 -
California files suit against PBMs over insulin prices
The state filed suit Thursday against pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx, alleging they worked with drugmakers to drive up the price of insulin.
By Hailey Mensik • Jan. 13, 2023 -
HHS lays out timing for drug price negotiations
The agency will begin discussions on how it will negotiate Medicare drug prices in the spring and publish a list of the first 10 drugs selected by Sept. 1, 2023.
By Christopher Newman • Jan. 11, 2023 -
Sanders to target healthcare costs as leader of influential Senate committee
The longtime congressman and “Medicare for All” proponent will soon assume leadership of the Senate HELP committee, giving him sway in one of the nation’s most broadly influential health policy forums.
By Sydney Halleman • Jan. 9, 2023